{
    "clinical_study": {
        "@rank": "152855", 
        "arm_group": [
            {
                "arm_group_label": "Bevacizumab & Cisplatin", 
                "arm_group_type": "Experimental", 
                "description": "Bevacizumab 300mg plus Cisplatin 60mg by intrapleural given every two weeks"
            }, 
            {
                "arm_group_label": "Cisplatin", 
                "arm_group_type": "Active Comparator", 
                "description": "Cisplatin 60mg by intrapleural given every two weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine the efficacy and Safety of intrapleural Bevacizumab and  cisplatin as a\n      treatment for malignant pleural effusions (MPE) in patients with non-small cell lung cancer\n      (NSCLC)."
        }, 
        "brief_title": "Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Malignant Pleural Effusion", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Pleural Effusion", 
                "Pleural Effusion, Malignant"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with advanced recurrent or progressive NSCLC proven cytohistologically\n\n          -  Karnofsky performance status (KPS) \u226560\n\n          -  Life expectancy \u2265 2 months\n\n          -  No history of severe diseases of major organs including liver, heart, and kidney\n\n          -  No previous intrapleural therapy\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Active thoracic cavity or systemic bleeding\n\n          -  Active pleural or systemic infection.\n\n          -  Known sensitivity to Bevacizumab or Cisplatin\n\n          -  Refusal to participate in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01661790", 
            "org_study_id": "PLA304DN-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bevacizumab & Cisplatin", 
                "description": "Bevacizumab300mg&Cispltin60mg by intrapleural administration of each 2 week", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": "Avastin"
            }, 
            {
                "arm_group_label": [
                    "Bevacizumab & Cisplatin", 
                    "Cisplatin"
                ], 
                "description": "Cisplatin 60mg,intrapleural administration,Q2W", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug", 
                "other_name": "Cisplatin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bevacizumab", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Bevacizumab;", 
            "non-small cell lung cancer;", 
            "malignant pleural effusion;", 
            "intrapleural administration"
        ], 
        "lastchanged_date": "August 27, 2012", 
        "location": {
            "contact": {
                "email": "lixiaosong@hotmail.com", 
                "last_name": "xiaosong Li"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100048"
                }, 
                "name": "PLA 304 hospital"
            }, 
            "investigator": {
                "last_name": "Nan Du", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Open-labled, Randomized, Multicenter Phase III Study of Adjuvant Chemotherapy Comparing Bevacizumab Plus Cisplatin With Cisplatin Regimen in Malignant Pleural Effusion of Advanced Stage Non-Small-Cell Lung Cancer Patients", 
        "other_outcome": {
            "measure": "Quantitative RT-PCR for VEGF-A.", 
            "safety_issue": "No", 
            "time_frame": "before intrapleural administration"
        }, 
        "overall_contact": {
            "email": "dunan05@yahoo.com.cn", 
            "last_name": "Nan Du"
        }, 
        "overall_official": {
            "affiliation": "PLA 304 hospital", 
            "last_name": "Nan Du", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall Response Rate (ORR, percentage of patients who achieve CR and PR)", 
            "safety_issue": "No", 
            "time_frame": "baseline to measured progressive disease biweekly"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01661790"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese PLA General Hospital", 
            "investigator_full_name": "DuNan", 
            "investigator_title": "director of oncology department in PLA 304 hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "median Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "baseline to biweekly,until disease progression"
            }, 
            {
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "randomization to four weeks,until death"
            }, 
            {
                "measure": "adverse reactions", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 1 month after the last treatment"
            }, 
            {
                "measure": "Qualify of Life (QoL)", 
                "safety_issue": "No", 
                "time_frame": "baseline to biweekly,until death"
            }
        ], 
        "source": "Chinese PLA General Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Roche Pharma AG", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Chinese PLA General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}